Only two men can tell us if Elon Musk and Trump are truly, as of December 2025, “friends.” But the formal definition I used ...

The new analysis study showed the delay may stem from genetic mutations that are present when a child is born – but activate ...

Ultragenyx and Mereo BioPharma hit 52-week low after disappointing results from Phase 3 studies for Osteogenesis Imperfecta ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the AI stocks under $20 to buy now. On December 8, Recursion ...

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...

An in-depth look at Tianqiao Chen's argument that AI-native companies will dismantle traditional corporate structures, ...

A recent article in JAMA Internal Medicine describes a common genetic mutation found in many breast cancer patients who do not have a family history of the | Cancer ...

Flu season arrives with the holidays, as parties and travel kick into high gear and colder weather sets in across many states ...

It’s hard to keep up with all the discoveries made around the world every year in science, but harder still to sort the hype ...

New AI research tool can predict plasma cell cancer outcomes instantly by reading standard biopsy slides, boosting precision ...

Genetic sharing among evolutionary neighbors all happens through hybrids: the offspring produced when individuals from two species mate. Famous hybrids include offspring between polar and grizzly ...

Ultragenyx is developing setrusumab in pediatric and young adult patients across OI sub-types I, III and IV with two late-stage studies: the pivotal Phase 2/3 Orbit study and Phase 3 Cosmic study.